Bioadaptives, Inc. (BDPT): Cash & Equivalents
$215.2K
As of 2025-12-31
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $215.2K | -17.8% | 2026-04-14, Balance as of period end |
| 2024-12-31 | $261.9K | +195.7% | 2026-04-14, Balance as of period end |
| 2023-12-31 | $88.6K | n/c | 2025-04-15, Balance as of period end |
| 2022-12-31 | $82.9K | 0.0% | 2024-04-10, Balance as of period end |
| 2021-12-31 | $82.9K | n/m | 2023-03-31, Balance as of period end |
| 2020-12-31 | $4.6K | -62.7% | 2021-03-30, Balance as of period end |
| 2019-12-31 | $12.3K | n/a | 2021-03-30, Balance as of period end |
| No annual figure between 2015-12-31 and 2019-12-31. | |||
| 2015-12-31 | $99 | -99.7% | 2016-04-14, Balance as of period end |
| 2014-12-31 | $37.9K | +103.5% | 2016-04-14, Balance as of period end |
| 2013-12-31 | $18.6K | n/a | 2015-04-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $215.2K | -17.8% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $3.12M | -26.7% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $5.89M | -33.5% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $3.0K | -99.8% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $60.18M | -43.0% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $58.7K | -9.5% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $43.76M | +18.5% |
| Genelux Corp (GNLX) | 2025-12-31 | $5.33M | -37.7% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $1.95M | -58.2% |
Compare BDPT, PRFX, TLPH, IBO side by side · Screen every company in Pharmaceutical Preparations ↗